1月9日 - ** 生物技术药物开发商 Ardelyx ARDX.O 的股价在盘前交易中上涨近 2%，达到 7.15 美元
** Piper Sandler将股票评级从 "中性 "上调至 "增持"；将目标价从10美元上调至16美元，较上一交易日收盘价约有128.57%的潜在上涨空间。
** 在该公司发布最新报告后，该公司治疗肠易激综合症伴便秘的口服药 Ibsrela (link) 的销售势头强于预期。
** 该券商称，近期能见度有所改善，而管理层修订后的长期展望则推进了该产品实现有意义的规模化之路，并认为这是可以实现的
** 11位分析师平均将该股评为 "强力买入"；中位数PT为11美元--数据由LSEG编制
** 截至上次收盘，ARDX 在过去 12 个月中上涨了约 31%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.